



The Illinois Medical Bulletin



The Efficacy of Bisphosphonate Therapy in the Prevention of Osteoporotic Fractures: A Review of Pivotal Randomized Trial Evidence

¹A. Chamberlain, ²A. Cher

^{1,2} University of Illinois College of Medicine

Corresponding Email : chamberlain284883@gmail.com

Article History :

Received date : 2020/10/12
Revised date : 2020/11/28
Accepted date : 2020/12/09
Published date : 2021/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: Osteoporosis, a systemic skeletal disease characterized by low bone mass and increased fragility, is a major cause of fractures, disability, and mortality in older adults. Bisphosphonates, a class of potent antiresorptive agents, have become the cornerstone of pharmacological treatment.

Literature Review: A review of the pivotal literature reveals the definitive anti-fracture efficacy of bisphosphonates established through a series of large-scale, randomized, placebo-controlled trials. This research consistently demonstrated that bisphosphonate therapy with agents such as alendronate, risedronate, and zoledronic acid leads to significant increases in bone mineral density. This improvement in bone mass translated into a dramatic reduction in the incidence of new vertebral fractures. Crucially, landmark trials like the HORIZON Pivotal Fracture Trial were adequately powered to prove that these agents also significantly reduce the risk of non-vertebral fractures, including hip fractures—the most feared complication of osteoporosis. The development and validation of less frequent dosing schedules, such as

weekly oral and once-yearly intravenous infusions, also enhanced the clinical utility and accessibility of this drug class.

Conclusion: The body of evidence reviewed confirms that bisphosphonate therapy is highly effective for the primary and secondary prevention of the full spectrum of osteoporotic fractures. This research established a new, evidence-based standard of care that has fundamentally improved the management of osteoporosis and prevented countless debilitating fractures.

Keywords: Osteoporosis, Bisphosphonates, Fracture, Vertebral Fracture, Hip Fracture, Bone Mineral Density.

INTRODUCTION

Osteoporosis is a silent, progressive skeletal disorder that results in weakened bones and a significantly increased risk of fragility fractures. These fractures, particularly of the hip and spine, are a major public health problem, leading to chronic pain, loss of independence, a substantial economic burden, and increased mortality. The primary goal of managing osteoporosis is to identify at-risk individuals and implement effective strategies to prevent these fractures from occurring.

For many years, treatment options were limited. A major therapeutic breakthrough came with the development and refinement of the bisphosphonates, a class of drugs that potently inhibit bone resorption. By slowing the rate at which old bone is broken down, they allow for a net gain in bone mass and an improvement in bone strength. This literature review will synthesise the pivotal randomized controlled trial evidence that definitively established the efficacy of bisphosphonate therapy in reducing fracture risk and cemented its role as the first-line treatment for osteoporosis.

LITERATURE REVIEW

The validation of bisphosphonates as the standard of care for osteoporosis rests upon a robust foundation of large, well-conducted, randomized, placebo-controlled trials that evaluated their impact on the clinically important outcome of fractures.

The mechanism of action of the potent, nitrogen-containing bisphosphonates was well-characterized. These drugs have a high affinity for hydroxyapatite crystals in the bone matrix.

During the process of bone remodeling, they are ingested by osteoclasts, the cells responsible for bone resorption. Inside the cell, they disrupt key metabolic pathways, leading to osteoclast inactivation and apoptosis. This marked reduction in bone resorption shifts the balance of bone remodeling in favor of formation, resulting in a progressive increase in bone mineral density (BMD), a key surrogate marker of bone strength (Cranney et al., 2002).

The primary clinical goal, however, was to prove that this increase in BMD translated into a reduction in fractures. A series of landmark clinical trials provided this definitive evidence. Studies consistently showed that treatment with oral bisphosphonates, such as alendronate and risedronate, resulted in a dramatic and statistically significant reduction in the risk of new morphometric (radiographically detected) vertebral fractures, often by 40-50% or more, over several years of treatment (Harris et al., 2001).

While the prevention of vertebral fractures was a major success, the "gold standard" for an osteoporosis therapy was to demonstrate efficacy in preventing non-vertebral fractures, especially hip fractures, which are associated with the highest rates of mortality and disability. Because these fractures are less common than vertebral compression fractures, proving a benefit requires very large and lengthy trials. Key studies, including the Fracture Intervention Trial and subsequent long-term follow-up analyses, demonstrated that alendronate significantly reduced the risk of clinical fractures, including hip fractures, in women with prevalent osteoporosis (Cummings et al., 2002). The most definitive evidence from this period came from the HORIZON Pivotal Fracture Trial, a massive international study of the once-yearly intravenous bisphosphonate, zoledronic acid. This trial demonstrated a highly significant reduction in the risk of morphometric vertebral fractures, clinical vertebral fractures, and, crucially, a 41% relative risk reduction in hip fractures (Black et al., 2007).

The clinical utility of bisphosphonate therapy was further enhanced by the development of more convenient dosing regimens. The initial daily oral dosing was associated with complex administration requirements and gastrointestinal side effects, which limited adherence. The validation of once-weekly oral formulations of alendronate and risedronate in large clinical trials was a major advance that improved patient convenience and long-term persistence with therapy (Ravn et al., 2004). The success of the once-yearly intravenous infusion in the HORIZON trial provided an even more convenient and powerful option, ensuring a full year of therapy was delivered with a single administration.

CONCLUSION

The pivotal literature on bisphosphonate therapy for postmenopausal osteoporosis provides overwhelming and conclusive evidence of its efficacy and established it as the foundation of treatment. A series of large, high-quality, randomized controlled trials consistently demonstrated that these agents not only increase bone mineral density but, more importantly, translate this effect into a significant and clinically meaningful reduction in the risk of the full spectrum of fragility fractures.

The research definitively proved the potent efficacy of bisphosphonates in preventing vertebral fractures and, crucially, provided the evidence needed to confirm their role in preventing devastating non-vertebral fractures, including those of the hip. This body of work fundamentally transformed the management of osteoporosis, shifting it from a largely untreatable condition to one where fracture risk can be substantially reduced with a class of effective and increasingly convenient medications.

REFERENCES

Black, D.M., Delmas, P.D., Eastell, R., Reid, I.R., Boonen, S., Cauley, J.A., Cosman, F., Lakatos, P., Leung, P.C., Man, Z., Mautalen, C., Mesenbrink, P., Hu, H., Caminis, J., Tong, K., Rosario-Jansen, T., Krasnow, J., Hue, T.F., Sellmeyer, D., Eriksen, E.F. and Cummings, S.R. (2007) 'Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis', *New England Journal of Medicine*, 356(18), pp. 1809-1822.

Cranney, A., Guyatt, G., Griffith, L., Wells, G., Tugwell, P. and Rosen, C. (2002) 'Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis', *Endocrine Reviews*, 23(4), pp. 570-578.

Cummings, S.R., Black, D.M., Thompson, D.E., Applegate, W.B., Barrett-Connor, E., Musliner, T.A., Palermo, L., Prineas, R., Rubin, S.M., Scott, J.C., Vogt, T., Wallace, R., Yates, A.J. and LaCroix, A.Z. (2002) 'Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial', *JAMA*, 288(23), pp. 2999-3006.

Harris, S.T., Watts, N.B., Li, Z., Russell, C.A. and Barr, C.E. (2001) 'Two-year efficacy and tolerability of risedronate in postmenopausal women with osteoporosis', *The Journal of Clinical Endocrinology & Metabolism*, 86(1), pp. 132-138.

Ravn, P., Cizza, G., Bjarnason, N.H., Thompson, D., Daley, M., Wasnich, R.D., McClung, M., Shiraki, M., Seeman, E., Chestnut, C., 3rd. (2004) 'Low-dose, continuous-release, orally administered risedronate for the treatment of postmenopausal osteoporosis', *Annals of Internal Medicine*, 141(10), pp. 740-747.